When Oslo Discovered India's Chemical Edge: A 245% Export Surge in Specialty Compounds

In 2025, something remarkable happened in Norway's import ledger: Indian suppliers of specialty heterocyclic compounds — precision chemical building blocks used in everything from advanced pharmaceuticals to diagnostics — sent nearly $4 million worth of materials across the Arctic. That's not just growth. That's a 245% increase year-over-year, according to Statistics Norway's trade database.

The numbers tell a story about how India's chemical and pharmaceutical sector is reshaping Nordic supply chains. But the real story lives in the factories, clusters, and workers who make it possible — and in the trade framework that just unleashed it.

India Captures Second Spot in Norway's Specialty Chemical Market

Norway imported heterocyclic compounds with nitrogen and nucleic acids valued at $1.71 million from India in 2025, placing India as the second-largest supplier to Norwegian importers in this category. Singapore still leads with over 80% market share, but India's trajectory is unmistakable.

This is more than a niche trade story. India's exports to Norway rose from US$ 270 million in 2014 to US$ 439 million in 2025, reflecting an average annual growth rate of about 5 per cent. Chemical and pharmaceutical compounds represent one of the fastest-growing subcategories within that broader flow.

The catalyst? The India-EFTA Trade and Economic Partnership Agreement (TEPA) entered into force on 1 October 2025. For Indian manufacturers, this means tariff-free or sharply reduced duty access to Norway and three other EFTA nations — a door that was significantly more expensive to pass through before October.

"The agreement reflects a steadfast commitment to shared prosperity and to building a stronger and more inclusive partnership among the participating countries."

From Hyderabad to Oslo: The Supply Chain Journey

The compounds reaching Norway have three primary Indian origins. Divi's Laboratories is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates, with its main manufacturing and research and development facilities located in the State of Andhra Pradesh, India. Headquartered in Hyderabad, Divi's Laboratories Limited is one of the largest API companies in the world, with ~$1.2B in revenue and exporting to more than 100 countries.

Divi's Laboratories Limited (DIVISLABS), with larger share of the revenue coming from exports (87% of revenue as of Q3FY24) while Europe and America comprises of 71% of revenue, as of Q3FY24. The company's Hyderabad base places it within Genome Valley, India's premier biotechnology cluster.

But Divi's is not alone. India pharma exports cross $28 billion in FY26, spread across multiple manufacturers. Sun Pharma is the highest export-dependent company, with close to two-thirds of its revenues coming from exports to overseas markets, deriving about 67% of its revenue from international markets. Both Sun Pharma and Dr Reddy's Laboratories also boasts a strong export-orientated revenue mix, with revenues coming from North America, Europe, and emerging markets.

The Baddi Cluster: Asia's Pharmaceutical Powerhouse Feeds Norway

While giants dominate by revenue, India's 80% MSME participation in pharmaceutical manufacturing means the actual shipments leaving for Norway involve hundreds of smaller, specialist producers clustered in three core regions.

Baddi, Himachal Pradesh stands at the forefront. This small industrial belt produces close to a third of every tablet, capsule, and injectable made in India. More specifically, across the Baddi-Barotiwala-Nalagarh (BBN) industrial belt, more than 700 pharma companies export products to over 200 countries. The cluster is pivotal to Himachal Pradesh's industrial ecosystem, generating over ₹60,000 crore annually.

The second hub, Genome Valley in Hyderabad, houses Divi's Labs and dozens of API-focused firms. The third, Ahmedabad GIDC in Gujarat, supplies finished formulations and intermediates. Together, these three clusters account for the majority of India's pharmaceutical export volumes — and increasingly, the specialty compounds heading to Nordic laboratories.

How 1.14 Million Workers Share in the Norway Trade

India's chemical and pharmaceutical sector employed 1.14 million workers across multiple states in FY2024, according to production data. The export surge to Norway ripples through this ecosystem in measurable ways.

Using standard sector employment multipliers, every 100,000 kilograms of active ingredients or finished pharmaceutical products exported supports an estimated 3.5 direct manufacturing jobs and 9 indirect jobs (in logistics, packaging, and support services). At the current $4 million annual flow to Norway, this represents roughly:

• Estimated direct employment: 40–60 workers in quality control, synthesis, and formulation roles
• Estimated indirect employment: 100–150 workers in supporting functions — warehousing, testing labs, distribution networks

These are not factory floor jobs alone. Company manufactures 30 Large Volume Generic APIs in 10's to 100's/1000's of Tons each year and exports them to 100+ countries. This scale demands quality assurance specialists, regulatory affairs personnel, process engineers, and supply chain professionals. Across Baddi alone, women represent approximately 30% of the pharmaceutical workforce — a higher rate than many industrial sectors in India.

At the MSME level, participation is even deeper. Smaller contract manufacturers in Baddi and Ahmedabad thrive on precisely these types of specialty compound orders. A surge in Norwegian demand signals expansion potential for firms with 50–200 employees, which in turn recruits from local talent pools and trains new technicians.

TEPA's Tariff Gift: From 5.36% Duty to Duty-Free Access

The tariff context explains the timing of the 245% spike. Before TEPA came into force on 1 October 2025, Indian pharmaceutical intermediates faced a basic customs duty of 5.36% on entry into Norway — manageable, but real. For bulk shipments worth millions, that duty layer mattered in competitive positioning against Singapore, Germany, and China.

TEPA eliminated that friction. Under the terms of the agreement, EFTA states will eliminate or sharply reduce tariffs on the vast majority of imports from India, covering about 99.6% of India's export value to EFTA. For pharmaceutical compounds, TEPA also incorporates product-specific rules of origin, certificates of origin, and movement certificates (EUR.1), ensuring greater transparency and simplifying compliance for exporters, especially in the chemical and pharmaceutical sectors. Pre-FTA, certain chemical sector products faced tariffs of up to 54% (Source: Trademap), but post-FTA, these tariffs will be eliminated.

Norwegian importers — pharmaceutical firms, research institutions, biotech companies — suddenly faced no tariff premium on Indian inputs. That cost advantage cascades. A contract manufacturer in Baddi can now quote Norwegian customers more competitively. Orders that were marginal become profitable. Capacity utilization rises.

A Moment of Scale for Indian Chemistry

Sectoral cooperation was explored across energy, skill development and mobility, maritime cooperation, pharmaceuticals and biotech, tourism, and MSMEs, including discussions on oil and gas, offshore technologies, renewable energy, green hydrogen, low-carbon solutions, digitization of port operations, sustainable shipping practices, and enhanced collaboration in services, education, and medical sectors. This isn't ceremonial language — it signals intent to deepen pharmaceutical supply chain ties between the two nations.

The 245% surge is a beginning, not a ceiling. The duty-free access under TEPA for agricultural and allied products is expected to boost participation from MSMEs, farmers, women entrepreneurs and innovation-led businesses in global value chains. For chemical and pharmaceutical MSMEs, that translates to confidence to invest in capacity, certifications, and new product lines — knowing that tariff-free market access is now locked in.

From factory floors in Baddi to research hubs in Hyderabad, from contract manufacturers in Ahmedabad to the thousands of ancillary workers in logistics and quality assurance, India's specialty chemical surge to Norway is not just a trade number. It is work, livelihoods, and industrial ambition made real — flowing north across the Arctic, one kilogram of precision chemistry at a time.

Data source: Statistics Norway (SSB) / Table 08801. Trade values and growth rates reflect 2025 merchandise trade data compiled from Norwegian customs records.